Evidence map›Paper›PMID 39628691›Full record

ReviewInternational journal of medical sciences2024

Research Progress on the Application of CGM in Patients with Diabetes and Hemodialysis.

Ping Huang, Jing He, Liansheng Ren, Rong Yang, Dan Feng, Ling Li, Shuhuan Liu, Yunmin Wang, Yi Zeng, Wei Zhang and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ping Huang363 Hospital, 108 Daosangshu Street, Wuhou District, Chengdu, 610000, People's Republic of China.
Jing HeCenter for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, 150081, People's Republic of China; National Health Commission & Education Bureau of Heilongjiang Province, Key Laboratory of Etiology and Epidemiology, Harbin Medical University (23618504), Harbin, 150081, People's Republic of China; Center for Chronic Disease Prevention and Control, Harbin Medical University, Harbin, People's Republic of China.
Liansheng Ren363 Hospital, 108 Daosangshu Street, Wuhou District, Chengdu, 610000, People's Republic of China.
Rong Yang363 Hospital, 108 Daosangshu Street, Wuhou District, Chengdu, 610000, People's Republic of China.
Dan Feng363 Hospital, 108 Daosangshu Street, Wuhou District, Chengdu, 610000, People's Republic of China.
Ling Li363 Hospital, 108 Daosangshu Street, Wuhou District, Chengdu, 610000, People's Republic of China.
Shuhuan Liu363 Hospital, 108 Daosangshu Street, Wuhou District, Chengdu, 610000, People's Republic of China.
Yunmin Wang363 Hospital, 108 Daosangshu Street, Wuhou District, Chengdu, 610000, People's Republic of China.
Yi Zeng363 Hospital, 108 Daosangshu Street, Wuhou District, Chengdu, 610000, People's Republic of China.
Wei ZhangCenter for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, 150081, People's Republic of China; National Health Commission & Education Bureau of Heilongjiang Province, Key Laboratory of Etiology and Epidemiology, Harbin Medical University (23618504), Harbin, 150081, People's Republic of China; Center for Chronic Disease Prevention and Control, Harbin Medical University, Harbin, People's Republic of China.
Dan Zhu363 Hospital, 108 Daosangshu Street, Wuhou District, Chengdu, 610000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus is the main cause of end-stage renal disease (ESKD), and most patients need hemodialysis (HD) treatment after they progress to uremia. Patients with diabetes and HD have obvious blood glucose fluctuation, hyperglycemia and hypoglycemia may both related to the higher mortality. Therefore, maintaining blood glucose stability is the main treatment strategy to improve the prognosis of patients. It is challenging to evaluate the blood glucose control of patients with diabetes and HD. The traditional blood glucose detection methods have certain limitations, they may be affected by many factors in HD patients. The application of continuous glucose monitoring (CGM) system is gradually recognized, CGM can monitor blood glucose real-time, timely, and predictive capabilities, there are fewer factors that are affected blood glucose in HD patients.

Indexed as

Blood GlucoseContinuous Glucose MonitoringKidney Failure, ChronicRenal DialysisDiabetes MellitusHumansHypoglycemiaBlood GlucoseBlood glucose fluctuationContinuous Glucose MonitoringDiabetes MellitusHemodialysis

Identifiers

PMID39628691
PMCPMC11610330

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.